CD4 and coinfection: Of the total participants, 158 (28.2%) and 26 (4.6%) were in WHO stage III and IV, respectively, at the baseline, 100 (17.8%) had TB co-infection, 494 (88.1%) received OIP, and 358 (63.8%) had a baseline CD4 count of more than 200.